Louisiana 2025 Regular Session

Louisiana House Bill HB15

Introduced
2/25/25  
Refer
2/25/25  
Refer
4/14/25  
Report Pass
5/7/25  
Engrossed
5/14/25  
Refer
5/19/25  
Report Pass
5/28/25  
Enrolled
6/3/25  
Chaptered
6/8/25  

Caption

Adds certain substances to the Uniform Controlled Dangerous Substances Law

Impact

By adding these substances to Schedule I, the bill enhances the state's ability to control and monitor their usage, aligning with national trends addressing the opioid epidemic and other drug-related issues. The implications of this law extend to law enforcement agencies, which will be empowered to crack down on illegal distribution, thereby enhancing public safety. Additionally, health professionals may experience a shift in their approach to treating patients, especially in pain management scenarios where these substances may have previously been utilized.

Summary

House Bill 15 aims to amend the Uniform Controlled Dangerous Substances Law in Louisiana by adding new substances to its Schedule I list. Specifically, the bill introduces N-Desethyl isotonitazene and Etonitazepipne, which are designed to regulate the use and distribution of these potent substances within the state. This action reflects an ongoing effort to manage and mitigate the risks associated with emerging drugs that pose significant health threats.

Sentiment

The sentiment surrounding HB 15 appears to be predominantly supportive, reflecting a bipartisan agreement on the need to address the dangers posed by new drug compounds. Lawmakers and health experts alike seem to recognize the importance of proactive measures in public health legislation, particularly in relation to drug enforcement. However, there may be concerns related to overreach and the adequacy of existing treatment alternatives for patients who utilize similar substances for legitimate medical purposes.

Contention

Potential points of contention around HB 15 could center on the balance necessary between regulation and access to care. While the aim is to reduce the availability of dangerous substances, stakeholders may argue about the implications for patients who require these drugs for legitimate health issues. The law may also face scrutiny from local communities regarding how effectively it addresses the broader spectrum of substance abuse and addiction, especially considering the diverse needs of different populations across Louisiana.

Companion Bills

No companion bills found.

Previously Filed As

LA HB204

Adds substances to the Uniform Controlled Dangerous Substances Law

LA SB14

Provides relative to schedules of the Uniform Controlled Dangerous Substances Law. (8/1/23)

LA SB94

Adds certain substances to the Uniform Controlled Dangerous Substance Law. (8/1/23)

LA HB106

Adds Xylazine to Schedule II of the Uniform Controlled Dangerous Substances Law

LA HB830

Adds Tianeptine to Schedule I of the Uniform Controlled Dangerous Substance Law

LA SB17

Adds Tianeptine to Schedule I of the Uniform Controlled Dangerous Substance Law. (8/1/24)

LA HB14

Provides relative to Schedule I of the Uniform Controlled Dangerous Substances Law (EG SEE FISC NOTE See Note)

LA HB735

Provides relative to penalties for distribution or possession with intent to distribute certain controlled dangerous substances (OR SEE FISC NOTE GF EX)

LA HB492

Repeals a tax on marijuana and controlled dangerous substances (OR DECREASE GF RV See Note)

LA SB49

Increases penalties for the crime of creation or operation of a clandestine laboratory for the unlawful manufacture of certain controlled dangerous substances. (8/1/23) (EN INCREASE GF EX See Note)

Similar Bills

No similar bills found.